A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2014
At a glance
- Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
- Indications Malignant melanoma; Neuroblastoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- 01 Oct 2005 New trial record.